Journal ArticleDOI
Length of clinical trials of dementia drugs : Position paper from the international working group on harmonization of dementia drug guidelines
Douglas Galasko,David A. Bennett,Mary Sano,Chris Ernesto,Ronald G. Thomas,Michael Grundman,Steven H. Ferris +6 more
TLDR
This paper developed a set of informant-based items describing performance of activities of daily living (ADL) by patients with Alzheimer's disease (AD) to identify which ADL are useful for assessment of patients in clinical trials.Abstract:
SummaryWe developed a set of informant-based items describing performance of activities of daily living (ADL) by patients with Alzheimer's disease (AD) to identify which ADL are useful for assessment of patients in clinical trials. Evaluation of ADL is an important outcome measure in AD clinical triread more
Citations
More filters
Journal ArticleDOI
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics.
TL;DR: It is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloids-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Journal ArticleDOI
Memantine in Moderate-to-Severe Alzheimer's Disease
Barry Reisberg,Rachelle S. Doody,Albrecht Stöffler,Frederick A. Schmitt,Steven H. Ferris,Hans Jörg Möbius +5 more
TL;DR: Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available.
Journal ArticleDOI
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody,Ronald G. Thomas,Martin R. Farlow,Takeshi Iwatsubo,Bruno Vellas,Steven Joffe,Karl Kieburtz,Rema Raman,Xiaoying Sun,Paul S. Aisen,Eric Siemers,Hong Liu-Seifert,Richard C. Mohs +12 more
TL;DR: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with mild Alzheimer's disease.
Journal ArticleDOI
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Pierre N. Tariot,Martin R. Farlow,George T. Grossberg,Stephen M. Graham,Scott D. McDonald,Ivan Gergel +5 more
TL;DR: In patients with moderate to severe AD receiving stable doses of donepezil, memantine resulted in significantly better outcomes than placebo on measures of cognition, activities of daily living, global outcome, and behavior and was well tolerated.
Journal ArticleDOI
Rivastigmine for Dementia Associated with Parkinson's Disease
Murat Emre,Dag Aarsland,Alberto Albanese,E. J. Byrne,Günther Deuschl,P.P. De Deyn,Franck Durif,Jaime Kulisevsky,T. van Laar,Alan Lees,Werner Poewe,A Robillard,MM Rosa,Erik Ch. Wolters,P Quarg,Sibel Tekin,Roger Lane +16 more
TL;DR: In this paper, the effects of the dual cholinesterase inhibitor rivastigmine in patients with mild-to-moderate dementia associated with Parkinson's disease were investigated.